Atypical antipsychotics (Second generation) updated on 06-10-2025

Elective/induced termination of pregnancy

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3876
R8232
Ozturk, 2016 Elective termination of pregnancy during pregnancy (anytime or not specified) retrospective cohort unexposed (general population or NOS) Adjustment: No 4.66 [1.18;18.43] C 3/15   14/275 17 15
ref
S2329
R2701
Bellet - Aripiprazole, 2015 Voluntary abortions 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 5.78 [1.49;22.40] 8/86   3/172 11 86
ref
S2341
R8720
Habermann (Control exposed to FGA), 2013 Elective termination of pregnancy during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.26 [0.79;2.01] C
excluded (control group)
68/561   28/284 96 561
ref
S2385
R8721
Habermann (Control unexposed, disease free), 2013 Elective termination of pregnancy during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No 7.23 [4.38;11.93] C 68/561   21/1,122 89 561
ref
S2389
R8154
Paulus - Aripiprazole only, 2013 Elective terminations of pregnancy (early) 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 7.29 [2.43;21.87] C 11/68   5/194 16 68
ref
S2391
R2954
Vial (Control exposed to FGA), 2009 Elective termination of pregnancy 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No Matched 0.99 [0.47;2.10] C
excluded (control group)
13/89   21/143 34 89
ref
S2390
R2953
Vial (Control unexposed, NOS), 2009 Elective termination of pregnancy 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 4.18 [1.60;10.89] C 13/89   7/178 20 89
ref
S2346
R2804
Paulus, 2005 Elective termination of pregnancy 1st trimester prospective cohort unexposed, disease free Adjustment: No 11.59 [5.54;24.26] C 20/95   13/578 33 95
ref
Total 6 studies 7.17 [5.12;10.04] 186 914
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ozturk, 2016Ozturk, 2016 4.66[1.18; 18.43]17156%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Bellet - Aripiprazole, 2015Bellet - Aripiprazole, 2015 5.78[1.49; 22.40]11866%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: unclearROB reporting: moderate Habermann (Control unexposed, disease free), 2013Habermann, 2013 1 7.23[4.38; 11.93]8956145%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: low Paulus - Aripiprazole only, 2013Paulus - Aripiprazole only, 2013 7.29[2.43; 21.87]16689%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: unclearROB mesure: unclearROB reporting: unclear Vial (Control unexposed, NOS), 2009Vial, 2009 2 4.18[1.60; 10.89]208912%ROB confusion: unclearROB selection: unclearROB classification: moderateROB missing: unclearROB mesure: unclearROB reporting: unclear Paulus, 2005Paulus, 2005 11.59[5.54; 24.26]339521%ROB confusion: criticalROB selection: unclearROB classification: unclearROB missing: unclearROB mesure: unclearROB reporting: unclear Total (6 studies) I2 = 0% 7.17[5.12; 10.04]1869140.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Control unexposed, disease free; 2: Control unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 7.17[5.12; 10.04]1869140%NAOzturk, 2016 Bellet - Aripiprazole, 2015 Habermann (Control unexposed, disease free), 2013 Paulus - Aripiprazole only, 2013 Vial (Control unexposed, NOS), 2009 Paulus, 2005 6 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 7.17[5.12; 10.04]1869140%NAOzturk, 2016 Bellet - Aripiprazole, 2015 Habermann (Control unexposed, disease free), 2013 Paulus - Aripiprazole only, 2013 Vial (Control unexposed, NOS), 2009 Paulus, 2005 6 Tags Adjustment   - No  - No 7.17[5.12; 10.04]1869140%NAOzturk, 2016 Bellet - Aripiprazole, 2015 Habermann (Control unexposed, disease free), 2013 Paulus - Aripiprazole only, 2013 Vial (Control unexposed, NOS), 2009 Paulus, 2005 6 All studiesAll studies 7.17[5.12; 10.04]1869140%NAOzturk, 2016 Bellet - Aripiprazole, 2015 Habermann (Control unexposed, disease free), 2013 Paulus - Aripiprazole only, 2013 Vial (Control unexposed, NOS), 2009 Paulus, 2005 60.550.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-2.93.60.8420.000Ozturk, 2016Bellet - Aripiprazole, 2015Habermann (Control unexposed, disease free), 2013Paulus - Aripiprazole only, 2013Vial (Control unexposed, NOS), 2009Paulus, 2005

Asymetry test p-value = 0.4068 (by Egger's regression)

slope=2.3051 (0.3895); intercept=-0.8568 (0.9253); t=0.9260; p=0.4068

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 2391, 2341

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 7.17[5.12; 10.04]1869140%NAOzturk, 2016 Bellet - Aripiprazole, 2015 Habermann (Control unexposed, disease free), 2013 Paulus - Aripiprazole only, 2013 Vial (Control unexposed, NOS), 2009 Paulus, 2005 6 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.18[0.79; 1.75]1306500%NAHabermann (Control exposed to FGA), 2013 Vial (Control exposed to FGA), 2009 20.510.01.0